{"id":"abiraterone-treatment-c","safety":{"commonSideEffects":[{"rate":"42%","effect":"Fatigue"},{"rate":"38%","effect":"Hypertension"},{"rate":"35%","effect":"Diarrhea"},{"rate":"34%","effect":"Nausea"},{"rate":"32%","effect":"Muscle spasm"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Abiraterone acetate is a synthetic, irreversible inhibitor of CYP17, a key enzyme in the biosynthesis of androgens.","oneSentence":"CYP17 inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:51:52.903Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"}]},"trialDetails":[{"nctId":"NCT04577833","phase":"PHASE1","title":"A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-13","conditions":"Prostatic Neoplasms","enrollment":136},{"nctId":"NCT06632977","phase":"PHASE2","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-06","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":474},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT02711137","phase":"PHASE1, PHASE2","title":"Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2016-05-18","conditions":"Solid Tumors","enrollment":137},{"nctId":"NCT05733351","phase":"PHASE1","title":"Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2023-08-03","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":4},{"nctId":"NCT04262154","phase":"PHASE2","title":"Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-03","conditions":"Metastatic Prostate Cancer","enrollment":28},{"nctId":"NCT04597411","phase":"PHASE1","title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","status":"RECRUITING","sponsor":"Endocyte","startDate":"2021-04-01","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":99},{"nctId":"NCT02649790","phase":"PHASE1, PHASE2","title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2016-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":277},{"nctId":"NCT05067140","phase":"PHASE1, PHASE2","title":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-02","conditions":"Prostate Cancer Metastatic","enrollment":152},{"nctId":"NCT01957436","phase":"PHASE3","title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-11-13","conditions":"Metastatic Prostate Cancer","enrollment":1173},{"nctId":"NCT04726332","phase":"PHASE1","title":"Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)","status":"TERMINATED","sponsor":"Exelixis","startDate":"2021-02-10","conditions":"Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer","enrollment":52},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":"Prostate Cancer","enrollment":112},{"nctId":"NCT02991911","phase":"PHASE1","title":"A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-01-06","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":33},{"nctId":"NCT02456571","phase":"","title":"CTC Immune Checkpoint","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11","conditions":"Prostate Cancer","enrollment":38},{"nctId":"NCT02230046","phase":"PHASE1","title":"Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10","conditions":"Healthy","enrollment":102},{"nctId":"NCT01897389","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-07","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT01575587","phase":"PHASE1","title":"A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Pharmacology","enrollment":51},{"nctId":"NCT01678573","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-07","conditions":"Healthy","enrollment":15},{"nctId":"NCT01640093","phase":"PHASE1","title":"A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-05","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT01798628","phase":"PHASE1","title":"A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients","status":"COMPLETED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2009-09","conditions":"Healthy Volunteers","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Abiraterone: Treatment C","genericName":"Abiraterone: Treatment C","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CYP17 inhibitor Used for Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}